|
|
|
|
|
|||||||
|
Session 69
Poster Session
Immunopathogenesis Issues Addressed by Therapeutic Interventions 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 484-M. | Increased T-Cell Turnover with HIV Infection Correlates Strongly with Immune Activation and does not Normalize after 52 Weeks of HAART K. Anthony*, I. Sereti, B. Herpin, J. A. Metcalf, H. C. Lane, and M. A. Polis NIAID, NIH, Bethesda, MD
| ||
| 485-M. | Declines in CD4+ T-Cell Proliferation Rates Significantly Contribute to Increases in CD4+ T-Cell Telomere Length and TREC Levels in HIV-Infected Patients Undergoing HAART D. Prieto1, J. Kovacs2, V. Natarajan1, D. Douek3, C. Yoder2, I. A. Sidorov4, J. W. Adelsberger1, J. A. Metcalf3, R. Stevens1, R. Koup3, M. W. Baseler1, D. S. Dimitrov4, R. T. Davey3, M. A. Polis3, and R. A. Lempicki*1 1SAIC, Frederick, MD; 2Clin. Ctr.; 3NIAID; and 4NCI, NIH, Bethesda, MD
| ||
| 486-M. | Individuals with Discordant Immunological Responses Following Combination Antiviral Therapy Have Elevated Levels of T-Cell Receptor Excision Circles Despite Increased Levels of T-Cell Proliferation S. Lewin*1,2, A. Solomon1, P. U. Cameron1, S. M. Crowe3,4, and J. Hoy2 1Univ. of Melbourne; 2Royal Melbourne Hosp; 3Burnet Inst.; and 4Alfred Hosp., Melbourne, Australia
| ||
| 487-M. | Discordant Responses during Antiretroviral Therapy: Role for Immune Activation and T-Cell Redistribution M. Hazenberg*1, S. Otto1, D. van Baarle1, S. Kostense1, F. Wit2, J. Lange2, D. Hamann1, and F. Miedema1 1CLB/Sanquin and Landsteiner Lab. of the Academic Med. Ctr., Univ. of Amsterdam and 2 Univ. of Amsterdam, The Netherlands
| ||
| 488-M. | The Effect of a Potent, 4-Drug Combination on Reducing HIV Unspliced mRNA and Proviral DNA in PBMC H. Mo*1, L. Lu1, M. King1, M. Louie2, M. Markowitz2, J. Rooney3, B. Dusak4, S. Brun1, B. Richards1, J. Leonard1, D. Kempf1, D. Ho2, E. Sun1, and A. Molla1 1Abbott Labs., Abbott Park, IL; 2Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; 3Gilead Sci., Foster City, CA; and 4Bristol-Myers Squibb, Wilmington, DE
| ||
| 489-M. | Immunologic Predictors of Discordance between CD4+ T-Cell and HIV-1 RNA Responses during Antiretroviral Therapy J. Spritzler*1, D. Mildvan2, A. Russo1, D. Asthana3, B. Schock4, D. Livnat5, J. Kagan5, A. Landay6, and D. W. Haas7 1Harvard Sch. Publ. Hlth., Boston, MA; 2Beth Israel Med. Ctr., New York, NY; 3Univ. of Miami, FL; 4Frontier Sci., Amherst, NY; 5NIAID, NIH, Bethesda, MD; 6Rush-Presbyterian Med. Coll., Chicago, IL; and 7Vanderbilt Univ., Nashville, TN
| ||
| 490-M. | Immunological and Virological Characteristics of HIV-Infected Patients with Discordant Response to Highly Active Antiretroviral Therapy S. Vella*1, G. D’Ettorre2, L. Palmisano1, E. Nicastri4, S. G. Parisi, M. Andreotti1, L. Sarmati3, C. M. Galluzzo1, C. Mastroianni2, V. Vullo2, E. Concia5, and M. Andreoni3 1Inst. Superiore di Sanità, Rome; 2Univ. La Sapienza, Rome; 3Univ. Tor Vergata, Rome; 4IRCCS L. Spallanzani, Rome; and 5Univ. of Verona, Italy
| ||
| 491-M. | Rapid Initial Decay of Latently Infected Cells Following the Re-Initiation of HAART in Chronically HIV-1-Infected Patients with Treatment Interruptions J. Blankson*1, J. Siliciano1, D. Finzi1, T. Quinn1,2, J. Gallant1, and R. Siliciano1 1Johns Hopkins Univ. Sch. of Med., Baltimore, MD and 2NIAID, NIH, Bethesda, MD
| ||
| 492-M. | Intrinsic Decay Rate of Lymphocyte Reservoirs of HIV-1 M. C. Strain1, D. Havlir1,2, H. Gunthard3, C. Ignacio1, T. Macaranas1, O. A. Daly4, M. Fischer3, M. Opravil3, A. J. Leigh-Brown1,2, H. Levine1, S. Kwok5, C. Christopherson5, D. Smith1, C. Spina1,4, D. D. Richman1,4, and J. K. Wong*1 1Univ. of California, San Diego; 2Antiviral Res. Ctr., San Diego, CA; 3Univ. Hosp., Zurich, Switzerland; 4VA San Diego Healthcare System, CA; and 5 Roche Molecular Diagnostics, Alameda, CA
| ||
| 493-M. | Levels of Cell-Free HIV Virions Released by Latently Infected, Resting CD4+ T Cells: Implications for Ongoing Viral Replication T. W. Chun*, J. Justement, P. Pandya, S. Liu, M. McLaughlin, L. Ehler, and A. S. Fauci NIAID, NIH, Bethesda, MD
| ||
| 494-M. | Peripheral Blood Dendritic Cells are not a Major Reservoir for HIV-1-Infected Individuals on Virally Suppressive HAART M. Otero*1, G. Nunnari1, G. Dornadula1, C. Patel1, I. Frank2, and R. J. Pomerantz1 1Thomas Jefferson Univ. and 2Univ. of Pennsylvania, Philadelphia
| ||
| 495-M. | Viral- and HIV-Specific CTL Dynamics during Intermittent Antiretroviral Therapy in Chronically HIV-Infected Patients A. Oxenius1, A. McLean1, M. Fischer2, R. Hafner2, C. Schneider2, H. Joller2, D. Price1, S. Dawson1, B. Hirschel3, R. Phillips1, R. Weber2, and H. Gunthard*2 for the Swiss HIV Cohort Study 1Oxford Univ., UK and Univ. Hosp 2Zürich and 3Geneva, Switzerland
| ||
| 496-M. | Autologous Neutralizing Antibody (ANAB) to Concurrent and CD4 T-Cell-Recovered Virus in HIV Infected Children on HAART N. Ching*1, L. Wei1, J. Deville1, K. Nielsen1, S. Wolinsky2, and Y. Bryson1 1Univ. of California, Los Angeles and 2Northwestern Univ., Chicago, IL
| ||
| 497-M. | Mucosal Cytokines/Chemokines are Increased by as much as 75-fold in HAART-Treated Subjects with Detectable Plasma Viral Loads Compared to Those with Fully Suppressed Viremia J. Elliott1, W.J. Boscardin1, M. Poles2, I. McGowan1, M. Fuerst1, P. Taing1, and P. Anton*1 1Univ. of California AIDS Inst., Los Angeles and 2New York Univ. Sch. of Med., New York
| ||
| 498-M. | Differential Gene Expression in Chronically Infected HIV Patients Initiating HAART and Long-Term HAART Recipients Interrupting Therapy G. Dennis*1, J. Yang1, M. Bosche1, D. Hosack1, B. Sherman1, I. A. Sidorov2, D. S. Dimitrov2, J. W. Adelsberger1, J. A. Metcalf3, R. Stevens1, M. W. Baseler1, R. T. Davey3, M. A. Polis3, H. C. Lane3, and R. A. Lempicki1 1SAIC, Frederick, MD; 2NCI and 3NIAID, NIH, Bethesda, MD
| ||
| 499-M. | Immune Correlates of a Discordant CD4/VL Response to PI-Based HAART S. Sufka*, G. Ferrari, G. Sempowski, H. Staats, V. Gryszowka, V. Teaberry, K. Weinhold, and C. Hicks Duke Univ. Med Ctr., Durham, NC
| ||
| 500-M. | Human Cytomegalovirus (HCMV)-Specific CD4+ and CD8+ T-Cell-Mediated Immunity in AIDS Patients following HAART G. Piccinini*1, D. Lilleri1, G. Comolli1, E. Genini1, L. Minoli1, A. D’Arminio2, M. Catalina3, L. Gibson3, K. Luzuriaga3, M. G. Revello1, and G. Gerna1 1IRCCS PoliClin. San Matteo, Pavia, Italy; 2Univ. of Milan, Italy; and 3Univ. of Massachusetts Med. Sch., Worcester
| ||
| 501-M. | Disease Stage Does Not Influence the Frequencies of HIV-1-Specific Th1 Cells after Long-Term of Highly Efficient Antiretroviral Therapy G. Carcelain*, N. Alatrakchi, A. Samri, R. Tubiana, C. Duvivier, S. Hilpert, V. Perrin, P. Debre, C. Katlama, and B. Autran Hosp. Pitié-Salpétrière, Paris, France
| ||
| 502-M. | Immune Reconstitution in HIV-Infected Children following Antiretroviral Therapy V. Haridas*, A. Chandrasekaran, S. Chavan, and S. Pahwa North Shore-Long Island Jewish Res. Inst. Immunology Ctr., Manhasset, NY
| ||
| 503-M. | Functional Restoration of Human Immunodeficiency Virus and Epstein-Barr Virus-Specific CD8+ T Cells during HAART Is Associated with an Increase in CD4+ T Cells D. van Baarle*1, S. Kostense1, S. Otto1, N.M. Nanlohy1, C. Jansen1, J. Lange1, 2, M.H.J. van Oers1, 2, and F. Miedema3 1Academic Med. Ctr., 2Intl. AIDS Evaluation Ctr., and 3Univ. of Amsterdam, The Netherlands
| ||
| 504-M. | Impaired Responses to Immunization in HIV-Infection despite CD4+ T-Cell Restoration after Suppressive Antiretroviral Therapy C. Lange*1,3, H. Valdez1, K. Medvik1, R. Asaad1, M. Wild2, R. Kalayjian2,, and M. Lederman1 1Univ. Hosp. and 2Metrohealth Hosp., Case Western Reserve Univ., Ctr. for AIDS Res., Cleveland, OH and 3Med. Clin., Res. Ctr., Borstel, Germany
| ||
| 505-M. | Persistence of Infectious HIV in both Memory and Naïve CD4 T-Cell Subsets in Patients on Prolonged and Effective HAART O. Lambotte1, A. Demoustier1, M. G. de Goer1, C. Wallon1, J. Gasnault1,2, C. Goujard1,2, J. F. Delfraissy1,2, and Y. Taoufik*1 1INSERM E-0109; 2Hosp. Bicêtre, Kremlin-Bicêtre and Univ. Paris-Sud, Bicetre, France
|
